Symptomatic Carotid Outcomes Registry
(SCORE Trial)

Recruiting in Palo Alto (17 mi)

+21 other locations

Overseen bySeemant Chaturvedi, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Maryland, Baltimore

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to build upon trials done over 30 years ago, which did not include statins, new antiplatelet agents, and newer antihypertensive medications. Since the landmark trials (NASCET, ECST), there have been new developments in medical stroke prevention, which creates a gap in knowledge. The aim of this study is to evaluate that clinical care with Intensive Medical Therapy (IMT) alone, the one year stroke rate in patients with symptomatic carotid stenosis and low risk clinical features will be \<5%.

Research Team

Seemant Chaturvedi, MD

Principal Investigator

School of Medicine, University of Maryland

Eligibility Criteria

Inclusion Criteria

Most recent stroke or TIA >2 weeks ago

Retinal ischemia only (amaurosis fugax, branch retinal artery occlusion (BRAO), central retinal artery occlusion (CRAO)

Age ≥40 years plus stroke or TIA ipsilateral to 50-99% ICA stenosis

See 5 more

Treatment Details

Interventions

Intensive Medical Therapy (Other)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Symptomatic carotid stenosis with low risk featuresExperimental Treatment1 Intervention

50-99% symptomatic carotid stenosis with low clinical or radiologic risk features (see inclusion criteria) Patients will receive intensive medical therapy, including dual antiplatelet therapy, high potency statins, BP control, and lifestyle modification